The adjuvant capacity of a novel vaccine vector "Gantrez-nanoparticles" (NP) towards coated or encapsulated ovalbumin (OVA) was investigated. OVA nanoparticles were prepared by a solvent displacement method previously described. The protein was incorporated during the manufacturing process (OVA-encapsulated nanoparticles) or after the preparation (OVA-coated nanoparticles). The mean size of the different nanoparticle formulations was lower than 300 nm, and the OVA content ranged approximately from 67 µg/mg nanoparticles (for OVA-coated nanoparticles) to 30 µg/mg nanoparticles (for OVA-encapsulated nanoparticles). All the OVA-NP formulations were capable of amplifying the antibodies titres (IgG1 and IgG2a) in mice after a single subcutaneous inoculation with respect free OVA or OVA adsorbed to Alum. Furthermore, the elicited response was, for some formulations, predominantly Th1 subtype. Thus, the formulation that contained mainly the antigen inside, and with a low concentration of cross-linking agent, displayed the best potential to induce a Th1 response after 35 days post-immunisation. These results are highly suggestive for the use of Gantrez nanoparticles as an efficient antigen delivery system, especially when a long lasting Th1 cytokine response is required.
Introduction
The optimization of the efficacy of vaccines relies on the development of effective adjuvants including the antigen delivery systems. Alum (aluminium hydroxide) and MF59 (an oil-in-water emulsion containing metabolizable oil squalene and the surfactants Tween 80 and sorbitan trioleate Span 85) are currently the only adjuvants that have been approved in most countries for vaccine administration in humans 1 . Unfortunately, they produce sometimes adverse reactions, they are poor inducers of cell mediated immunity, and multiple injections are generally necessary to maintain an adequate level and duration of immunity 2 . The single dose administration is an important pilar of the "gold standard" for vaccination, and controlled release of encapsulated antigens from biodegradable polymeric vectors (micro or nanoparticles) or other types of formulations such as liposomes 3 , virosomes [4] [5] [6] , ISCOMs (immunostimulatory complexes) 7 or virus-like particles 8, 9 may have here a key role. In this context, formulations based on PLGA copolymers, which include poly(lactide) homopolymer (PLA) and poly(lactide co-glycolide) copolymer (PLGA), have been approved for human use 10 . This kind of particulate vaccine delivery systems has a lot of advantages such as: i) the protection of the encapsulated active product against its enzymatic inactivation, ii) the increase of the stability of the material incorporated during the manufacturing process, transport and storage of such active product, iii) the improvement of the efficacy of the presentation to the antigen presenting cells (APC), and iv) the increase of the half life of the active product in the organism [11] [12] [13] .
One of the main criteria in the choice of a vaccine depends on the sort of the immune response elicited. The vaccine should be able to induce an immune response resulting in protection, and here, the sort of the immune response is very relevant. 4 Generally, the type (Th1 or Th2) and duration of the immune response mainly depends on physicochemical properties of the adjuvant vector such as size, polymeric nature, release profile (stability of the vectors) and antigen location on the particle 14 .
The summation of these physicochemical properties deeply affects the magnitude and the pathway of antigen presentations. Another important factor that can affect the antigen presentation is the complement activation and coating of the antigen loaded carriers. This property is also extremely related to the surface of the carriers 15 .
Therefore, we describe here, for the first time, the adjuvant capacity of Gantrez nanoparticles using OVA as antigen model. The effect of OVA location (coating the surface or encapsulated into the matrix) as well as the effect of cross-linkage of nanoparticles on the antibody immune response was also studied. Gantrez AN is a copolymer of methyl vinyl ether and maleic anhydride which can easily react with amino groups. In this context, previous studies have demonstrated its efficacy to load or link different types of proteins, such as bovine serum albumin (BSA) 16 and flagellin 17 .
Material and methods
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Preparation of Gantrez nanoparticles
Gantrez nanoparticles were prepared by a solvent displacement method previously described 16 . The model protein was incorporated during the manufacture process (OVA-loaded nanoparticles) or after the preparation of the adjuvant vectors (OVA-coated nanoparticles).
Preparation of OVA-coated Gantrez nanoparticles (NP I)
Gantrez copolymer 100 mg was dissolved in 5 mL acetone and poured into 20 mL of an ethanol: water phase (1:1 by volume) under magnetic stirring at room temperature. The organic solvents were eliminated under reduced pressure (Büchi R-144, Switzerland). The freshly prepared nanoparticles (NP) were incubated with 10 mg ovalbumin in 5 mL of water for 1 h at room temperature under magnetic stirring. The resulting carriers were purified by centrifugation at 27,000 x g for 20 min. The supernatants were removed and the pellets resuspended in water. The purification procedure was repeated twice and finally, the formulations were freeze-dried (Genesis 12EL, Virtis, USA) using sucrose (5%) as cryoprotector.
Preparation of OVA-encapsulated Gantrez nanoparticles (NP II, NP III and
NP IV) 6 Briefly, 5 mg OVA were dispersed in 1 mL acetone by ultrasonication 
Characterisation of Gantrez nanoparticles
The particle size and the zeta potential of nanoparticles were determined by photon correlation spectroscopy (PCS) and electrophoretic laser doppler anemometry, respectively, using a Zetamaster analyser system (Malvern Instruments, UK). The samples were diluted with distilled water and measured at room temperature with a scattering angle of 90º. All measurements were performed in triplicate.
The morphological characteristics of the nanoparticles were obtained by scanning electron microscopy (LEO Electron Microscopy Inc, Thornwood, NY)
operating at 3kV with a filament current of about 0.5 mA. Prior to observation, the nanoparticles were coated with a platinum laker of about 2 nm using a Cressington sputter-coated 208HR with a rotatory-planetary-tilt stage, equipped with a MTM-20 thickness controller. 7 The yield of the nanoparticles preparation process was determined by gravimetry from freeze-dried samples as described previously 16 .
The quantification of the amount of associated ovalbumin to nanoparticles was determined using the microbichinchoninic acid (Micro BCA) protein assay. For this purpose, the nanoparticulate pellet, obtained after centrifugation, was digested with NaOH 0.1N for 24 hours at 4ºC. Then, the resulting solutions were analysed in a spectrophotometer at 570 nm. Calibration curves from 1 to 100 µg/mL of OVA (r 2 >0.999) were performed using a control ovalbumin solution in NaOH 0.1N. Each sample was assayed in triplicate and results were expressed as the amount of ovalbumin (in µg) per mg nanoparticles. Similarly, the encapsulation efficiency (E.E.) was estimated as follows:
where Q initial is the initial amount of ovalbumin added per mg of polymer that form the NP and Q associated is the amount of encapsulated OVA per mg of NP.
In vitro release study of ovalbumin from nanoparticles
OVA-loaded nanoparticles (8 mg) were dispersed in eppendorf tubes by vortexing in 1 mL phosphate buffer saline (PBS, pH 7.4). Release study was conducted at 37±1ºC under rotating agitation during 7 days. At defined times, the sample tubes were centrifuged at 26,500 x g for 20 min and the protein content was determined in the supernatants by micro-BCA assay and performed in a 96-well multiscaner autoreader (Labsystems iEMS Reader MF). Empty nanoparticles were used as control and 8 subjected to the same procedure. Release profiles were expressed in terms of cumulative release, and plotted versus time.
Immunisation studies
Animal protocols were performed in compliance with the regulations of the Blood samples from the the retroorbital plexus were collected on days 0, 7, 14, 28 and 35 post-immunization. The samples were centrifuged (3000 x g, 10 min) and the resulting sera were pooled. Finally, each pool was diluted 1:10 in PBS and stored at -80ºC until analysis. Measurements were performed by triplicate and data were expressed as the reciprocal of a serum dilution whose optical density was 0.2 above blank samples.
Quantification of anti-OVA antibodies in serum
Evaluation of complement activation by 2-D immunoelectrophoresis of C3
The complement activation in the presence of different nanoparticles was evaluated by quantification of the conversion of C3 into C3b by 2-D immunoelectrophoresis using a polyclonal antibody to human C3. This technique was performed by a modification of a protocol previously described by Labarre et al 18 .
Briefly, human serum was obtained after calcifying plasma from healthy donors and stored at -80ºC until use. 
Statistical analysis
The physico-chemical characteristics were compared using the Student t-Test. P values <0.05 were considered significant. For the evaluation of the complement activation, statistical comparisons were performed using the one-way analysis of variance test (ANOVA) and Tukey HSD test. P<0.01 was considered as a statistically significant difference. All calculations were performed using SPSS ® statistical software program (SPSS ® 10, Microsoft, USA).
Results
Characterisation of Gantrez nanoparticles
The main physico-chemical characteristics of Gantrez formulations are summarised in Table 1 . The size of OVA-loaded nanoparticles was significantly higher than for empty nanoparticles (NP) (p<0.05). Thus, OVA-coated nanoparticles were found to be 2-times higher than empty nanoparticles. Besides, the size of OVA- Concerning the OVA content, it is interesting to note that, under our experimental conditions, the coating of nanoparticles enabled us to load 2-times more protein that the encapsulation process (i.e 68 vs 36 µg/mg). Furthermore, the crosslinkage process of nanoparticles (NP III and NP IV) also negatively affected the protein content and reductions of about 20% in the OVA entrapment were observed, comparing with NP II. Similarly, with increasing the DP concentration the nanoparticle yield decreased. Table 1 Figure 1 Figure 2 shows the in vitro release of OVA from nanoparticle formulations in PBS buffer. For OVA-coated nanoparticles, the protein release profile was characterised by a latency period of at least 6 hours, in which less than 5% of the loaded protein was 12 released, followed by a pulse of release of about 40% of the OVA content. On the contrary, OVA-encapsulated nanoparticles (NP-II, NP-III and NP-IV) displayed a profile characterised by a burst effect of about 10-20% of the loaded protein followed by a sustained period of slow release. Furthermore, cross-linkage with increasing amounts of DP reduce the release rate of OVA. Figure 3 shows the anti-OVA IgG 1 and IgG 2a titres (Th2 and Th1 markers, respectively) in sera after intradermal immunisation with the different formulations.
Figure 2
Antibody response in BALB/c mice
Concerning Th2 markers, all OVA-loaded nanoparticles (NP I, NP II, NP III and NP IV) displayed higher IgG 1 titres than the OVA-Alum group. In addition, all nanoparticle formulations appear to induce a similar profile of antibodies secretion, which was also different to that observe for the control group. This profile was characterised by a short lag-time, of about 1 week, followed by a rapid an intense period of anti-OVA IgG 1 secretion and, 14 days post-immunisation, a final and longer step of "plateau" of the antibody levels. At the end of the experiment (day 35), the highest IgG 1 titres were found for NP III and NP IV. In fact, cross-linked nanoparticles induced the production of 2-times higher levels of antibodies than NP II or 3-times higher than OVA-coated nanoparticles.
Furthermore, Gantrez nanoparticles were able to induce significative Th1 responses, characterized by the IgG 2a isotype, however some differences were observed among them. Thus, for NP II and NP III, the lag-time was of at least 7 days, whereas for NP I and NP IV, this perod was of at least 14 days. On the other hand, 35 days post- 13 immunization, NP I and NP II, appeared to reach a plateau, whereas NP III and NP IV were still increasing their antibody levels. On day 35, NP II displayed a IgG 2a titer which was found to be 2-times higher than for NP II and 5-times higher than for NP I. Figure 4 shows the percentage of C3b (activated C3) as an indicator of the complement activation induced by the nanoparticles after incubation in human serum containing divalent ions.
Figure 3
Activation of C3 in the presence of the nanoparticles
VBS-EDTA and serum incubated with divalent ions (VBS 2+ ) were used as negative controls. All Gantrez nanoparticles were found to have a higher ability to activate the complement comparing with nanoparticles reported previously to be good activators (Dex-An nanoparticles, described previously as strong activators, were incubated with a surface of 1000 cm 2 18 whereas in the present study they were incubated at 10 cm 2 ).
Nevertheless, under the experimental conditions described here, no significant differences between the different formulations tested (NP, NP I, NP II and NP IV) were found (p<0.001).
Figure 4
Discussion
Vaccination and immunotherapy are basic priorities for human and animal health, and a large number of adjuvants are therefore under investigation. Basically, polymeric adjuvant delivery-systems are able to get a prolonged antigen exposure by 14 facilitating the antigen uptake by the immune system cells. As a consequence, the delivery of encapsulated antigens results in more efficient immune activation than the equivalent amounts of free antigens [22] [23] [24] . Here, we describe the use of a novel vectoradjuvant based on nanoparticles of the polymer Gantrez, which is biocompatible and has been proposed as drug carrier for pharmaceutical applications 16, 25 . First of all, OVA loading percentage data demonstrated the efficiency of the method of preparation used here to get a different physical distribution of that antigen within the particle (OVA coating or encapsulation). All the nanoparticles displayed a similar and homogeneous size (See Table 1 and Figure 1 ), being slightly higher for NP I (nanoparticles with OVA coating the surface) than for OVA-encapulated formulations (NP II, NP III and NP IV) (See Table 1 ). The scanning electron microscopy of freezeddried formulations showed that the size of the nanoparticles was slightly lower than the one measured by photon correlation spectroscopy, what could be due to the swelling of the particles in aqueous media forming a "sponge" structure. This fact has been previously described for legumin nanoparticles by Mirshahi et al 26 .
On the other hand, as it was expected, the outer coating with OVA (NP I) rendered more electronegative particles with respect the ones that were formulated with OVA encapsulated. This fact demonstrated that in NP I, the OVA coated the nanoparticle surface. The zeta potential was also more negative as long as the amount of cross-linking agent increased.
Although OVA loading on NP I formulation was higher than OVA encapsulation in the other formulations (NP II, NP III and NP IV), the encapsulation efficiency was almost the same for all formulations. The yield of the process was also similar for the different nanoparticles, being approximately 80% as described previously by Arbos 16 .
The in vitro release studies, demonstrated that, as expected, the OVA release from NP I formulation (OVA coating the surface) was faster than from NP II, NP III and NP IV (OVA encapsulated) 27, 28 .
This fact can be easily related to the immune response. In this context, we observed that the elicited immune response after NP I administration was of lower 16 intensity than for the other formulations (See Figure 3) . Thus, we can estimate that most of the elicited antibody response by NP I was due to the OVA released just after the inoculation. These results suggest that both physical distribution of OVA and the consequent controlled release of the antigen exert an effect in the immunostimulating capacity of the nanoparticles.
On the other hand, cross-linkage with increasing amounts of DP slightly The complement activation data demonstrated that Gantrez nanoparticles can strongly activate the cleavage of C3 into C3b. This fact was corroborated comparing
Gantrez particles with Dex-An nanoparticles, used as positive control. These nanoparticles were described previously as strong activators when incubated with a surface of 1000 cm 2 but their capacity to activate complement was considerably reduced for the such low surface area used in the present work (10 cm 2 ) 18 . As well known, complement activation induces phagocytosis by macrophages 30 , thus, this strong activation of Gantrez nanoparticles could enhance the particle uptake by APCs. But the direct or indirect roles in the activation of APCs and induction of Th1/Th2 mediated immunity remain to be determined.
Finally, as a conclusion of this work, it can be remarked that Gantrez AN nanoparticles seemed to be a strong adjuvant. In this context, the titres elicited by intradermal administration of 10 µg of OVA in combination with the new nanoparticleadjuvant were found to exceed titers induced by immunization with the same amount of antigen. Furthermore, the induced titers were elicited with a relatively smaller amount of antigen used by other autors [31] [32] [33] , supporting the potential feasibility of our system.
Further benefits of this new antigen delivery system are currently being studied in vaccination and immunotherapy in animal models. 
